IMFINZI 120 mg injection IMFINZI contains Durvalumab, a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that binds to programmed cell death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and CD80 proteins. By inhibiting PD-L1 interactions, it releases the PD-L1/PD-1 mediated inhibition of the immune response, enhancing anti-tumor T-cell activity and immune recognition of cancer cells. It is indicated for the treatment of unresectable Stage III non-small cell lung cancer (NSCLC), extensive-stage small cell lung cancer (ES-SCLC), locally advanced or metastatic biliary tract cancer (BTC), and unresectable hepatocellular carcinoma (HCC).